1. Introduction {#s0005}
===============

Creatine is essential for the utilization of ATP at sites of high energy requirement such as muscle, brain and heart [@bb0005], [@bb0010]. In adult humans, about half of the creatine needed is obtained by dietary intake, mostly from meat and dairy products, and the other half is synthesized in the kidney and liver [@bb0015]. Creatine and its phosphorylated form, phosphocreatine, spontaneously break down to creatinine that is excreted in the urine [@bb0015]. The loss of creatine (as creatinine) is restored by new enzymatic synthesis and by dietary intake.

Creatine deficiency syndromes are a group of rare diseases that include two autosomal disorders of creatine biosynthesis (arginine: glycine amidinotransferase (AGAT) deficiency, OMIM [612718](612718){#ir0010}; and guanidinoacetate methyltransferase (GAMT) deficiency, OMIM [612736](612736){#ir0015}) and the X-linked creatine transporter deficiency (OMIM [300352](300352){#ir0020}) [@bb0020], [@bb0025], [@bb0030], [@bb0035].

The *SLC6A8* gene encodes the creatine transporter 1 (CT1 or CRTR), maps to Xq28 and is expressed in most human tissues, with highest levels found in skeletal muscle and kidney [@bb0040]. In the brain, the creatine transporter is strongly expressed, especially in the large projection neurons of the brain and spinal cord [@bb0045]. Defects in this transporter results in brain creatine deficiency that, in hemizygous males, is characterized by moderate to severe intellectual disability, delays in language and speech, autistic-like behavior, seizures in about 50% of cases, and mid-facial hypoplasia and short stature in some patients [@bb0050], [@bb0055], [@bb0060], [@bb0065].

The diagnosis of brain creatine deficiency is suspected based on clinical presentation with usually increased creatine/creatinine ratio and/or reduced brain creatine content by magnetic resonance spectroscopy, and confirmed by measurement of long-term creatine accumulation in fibroblasts and/or DNA sequencing of the *SLC6A8* gene [@bb0050], [@bb0065], [@bb0070], [@bb0075].

According to the LOVD website (Updated May 02, 2016), there are currently 141 unique DNA variants of the *SLC6A8* gene (<https://grenada.lumc.nl/LOVD2/vumc/home.php?select_db=SLC6A8>). The prevalence of *SLC6A8* mutations in males with X-linked intellectual disability is between 1 and 5.4% [@bb0050], [@bb0060], [@bb0080], [@bb0085], [@bb0090], [@bb0095], [@bb0100], [@bb0105], [@bb0110]. In this report, we describe three male patients with creatine transporter deficiency from Israel.

2. Case reports {#s0010}
===============

Patient 1 is a male who presented at 10 months of age with global developmental delay. He had failure to thrive, borderline microcephaly and significant hypotonia without dysmorphism. An initial MRI/MRS at 2 years of age identified non- specific changes in the white matter, but the lack of the creatine peak was not correctly identified at that time. A repeated MRI/MRS at 3 years of age demonstrated the lack of the creatine peak ([Fig. 1](#f0005){ref-type="fig"}A). Biochemical testing indicated increased urine creatine of 2.9 mmol/mol creatinine (normal 0.006--1.2 mmol/mol creatinine) with normal guanidinoacetate. At 8.5 years of age he has mild to moderate intellectual disability, significant language dyspraxia, and attended a special education school in special educational setting. The mother was low performing and has borderline microcephaly. She completed high school, but it is unknown whether she received a diploma. Her biochemical testing indicated normal urine creatine of 0.089 mmol/mol creatinine (normal range: 0.011--0.24 mmol/mol creatinine) and guanidinoacetate of 29.3 mmol/mol creatinine (normal range: 3--78 mmol/mol creatinine).

Patient 2, a male, was referred at 11 months of age for global developmental delay, axial hypotonia of trunk with hypertonicity of extremities. His MRI at 1.5 years of age was normal, but MRS demonstrated no creatine peak ([Fig. 1](#f0005){ref-type="fig"}B). Urine creatine was 3 mmol/mol creatinine (normal 0.006--1 mmol/mol creatinine) with normal guanidinoacetate. At 5.5 years of age, the patient has severe intellectual disability, 5--10 purposeful words, and walks independently with wide-based gait. The mother seemed to have functional and intellectual difficulties (with no microcephaly), but completed high school. It is unclear whether she received a diploma. She did not go through a formal evaluation, but MRS in the mother demonstrated a brain creatine peak lower than normal ([Fig. 1](#f0005){ref-type="fig"}C).

Patient 3, a male, presented at one year and 10 months of age with severe motor and language delays. The mother has normal intelligence and is normocephalic. Over time, the child acquired mild microcephaly. At 7.5 years he has speech apraxia, borderline intelligence with significant difference between verbal IQ (VIQ 48) to performance IQ (PIQ 102), and ADHD treated with methylphenidate. Urine creatine was 3 mmol/mol creatinine (normal 0.006--1.2 mmol/mol creatinine) with normal guanidinoacetate and subsequent brain MRS showed the absence of creatine peak ([Fig. 1](#f0005){ref-type="fig"}D).

3. Materials and methods {#s0015}
========================

3.1. Biochemical testing {#s0020}
------------------------

Measurement of plasma and urine guanidinoacetate, creatine and creatinine was performed using gas chromatography mass spectrometry in a hospital laboratory (Sheba Medical Center, Tel Hashomer, Israel) according to standard procedures [@bb0115].

3.2. Patients/samples {#s0025}
---------------------

Fibroblasts from the three pediatric patients as well as the mother of patient 2 and DNA samples from blood of the parents of patient 1 were collected according to an Institutional Review Board -approved protocol. Fibroblasts were cultured in DMEM supplemented with 15% fetal bovine serum and 1% [l]{.smallcaps}-glutamine. HELA cells were cultured in DMEM supplemented with 10% fetal bovine serum and 1% [l]{.smallcaps}-glutamine.

3.3. Creatine transports {#s0030}
------------------------

Creatine transport was measured at 37 °C with the cluster-tray method as previously described [@bb0110]. Briefly, cells were grown to confluence in 24-well plates (Costar) and depleted of intracellular amino acids by incubation for 60 min in Earle\'s balanced salt solution containing 5.5 mM [d]{.smallcaps}-glucose and supplemented with 0.5% bovine serum albumin. Cells were then incubated with [@bb0070]*C*-creatine 0.1 μCi/ml (Moravek Biochemicals, Brea, CA) containing the indicated concentration of cold creatine (2 μM) for 60 min. Non-saturable creatine transport was measured in the presence of 2 mM unlabeled substrate. The transport reaction was stopped by rapidly washing the cells 4 times with ice-cold 0.1 M MgCl~2~. Intracellular creatine was extracted from the cells with 0.5 ml of ice-cold ethanol and added to 5 ml of scintillation fluid for counting. Intracellular creatine was normalized for the protein content of each well and intracellular water content and expressed as nmol/ml cell water/h. Saturable creatine transport was calculated by subtracting transport in the presence of excess (2 mM) cold substrate from total transport and values are reported as means ± SE of 3--6 independent determinations.

3.4. DNA sequencing {#s0035}
-------------------

DNA was extracted from fibroblast cultures using MagNAPure Compact instrument (Roche Applied Science, Indianapolis, IN). The *SLC6A8* gene was sequenced using primers flanking each exon as previously described [@bb0080]. Sequence analysis was performed using BigDye v3.1 terminator and an ABI 3130xl (Applied Biosystems). Sequences were analyzed using the Mutation Surveyor software package (Softgenetics, State College, PA, USA).

3.5. HELA cell transfection {#s0040}
---------------------------

HELA cells were transfected using Lipofectamine-2000 (Invitrogen) and selected for 3 weeks with 400 mg/ml of G418 (Invitrogen). Stable transfectants were used for transport experiments.

Site Directed Mutagenesis was performed using QuikChange (Agilent) with a pCMV6-AC-GFP containing the cDNA of SLC6A8 as a template (Origene, RG209828).

4. Results and discussion {#s0045}
=========================

4.1. Creatine transport by human fibroblasts {#s0050}
--------------------------------------------

The clinical presentation and the laboratory results of plasma and urine guanidinoacetate, creatine and creatinine measurements suggested a defect in the creatine transporter. For this reason, a skin biopsy was obtained from each patient as well as the mother of the 2nd patient to confirm a defect in cellular creatine transport. Net creatine uptake in cells from all three patients was \< 10% of normal fibroblasts ([Fig. 2](#f0010){ref-type="fig"}). The fibroblasts from the mother of the second patient had normal creatine uptake ([Fig. 2](#f0010){ref-type="fig"}). These latter results show that in a population of cells with random X-inactivation the results of an inactivating mutation might not result in significant changes in creatine transport. A similar phenomenon might happen in the kidney, explaining why urinary creatine excretion is normal in most mothers of patients with X-linked creatine transporter deficiency.

The mothers of patients 1 and 2 appeared low functioning, but completed normal schooling and had normal social skills. The mother of patient 3 was completely normal, confirming the variability of the effects of mutations in the X-linked transporter gene in females.

4.2. DNA sequencing {#s0055}
-------------------

Sequencing of the *SLC6A8* gene encoding the creatine transporter indicated that patient 1 was hemizygous for c.619 C \> T (exon 3), resulting in a single amino acid substitution (p.R207W). His mother was heterozygous for this mutation. This missense mutation has not been previously reported, is predicted to be pathogenic using Polyphen2 and SIFT, and is not listed in the Exac browser in 60,000 normal individuals (<http://exac.broadinstitute.org/gene/ENSG00000130821>). This variant was submitted to the LOVD SLC6A8 database.

Patient 2 had a three base pair deletion (c.1222_1224 del TTC, p.F408del) on exon 8, reported as disease causing 14 times in the LOVD website (http://[www.LOVD.nl/SLC6A8](http://www.LOVD.nl/SLC6A8){#ir0035}), and in the HGMD website (<https://portal.biobase-international.com/hgmd/pro/gene.php?gene=SLC6A8>) from patients from Italy, USA, Spain, and Eastland Spain [@bb0075], [@bb0120], [@bb0125], [@bb0130], [@bb0135], [@bb0140], [@bb0145], [@bb0150]. This patient also had a c.1254 + 1 G \> A change, possibly affecting splicing, of unknown clinical significance. The mother of this patient had normal creatine uptake and was heterozygous for c.1222_1224delTTC, indicating that the second change on this allele was the result of a *de novo* mutation.

Patient 3 had a three base pair deletion, c.1006_1008delAAC (p.N336del), reported 20 times previously [@bb0050], [@bb0060], [@bb0155], [@bb0160], [@bb0165] and shown to cause defective creatine transport [@bb0155]. Overexpression of this variant in SLC6A8-deficient fibroblasts did not restore creatine uptake [@bb0170]. In addition this patient had an intronic deletion IVS1768-11_1768-9_delCTC which is not expected to cause a splice site problem (reported in LOVD). The mother of this patient was heterozygous for c.1006_1008delAAC plus the intronic IVS1768-11_1768-9_delCTC.

4.3. Creatine uptake {#s0060}
--------------------

The R207W substitution was introduced in the SLC6A8 cDNA by site-directed mutagenesis and stably transfected into Hela cells. Stably transfected cells were then tested for creatine uptake ([Fig. 3](#f0015){ref-type="fig"}). Creatine uptake increased more than twice in SLC6A8- transfected cells as compared to control Hela cells (58.7 versus 23.4 nmol/ml cell/h respectively). Introduction of the R207W substitution did not result in increased creatine transport (30.2 nmol/ml cell/h), confirming that this substitution impaired creatine transporter activity.

In summary, this report describes three patients from Israel with cerebral creatine deficiency with clinical and biochemical diagnosis of X-linked creatine transporter deficiency. The clinical presentation was of global development delay, without specific features. Fibroblasts for these patients had markedly reduced creatine uptake. DNA sequencing of the three patients, identified three different mutations in the *SLC6A8* gene, one of which was novel (p.R207W). Expression of this novel p.R207W mutation in HeLa confirmed its causative role in reducing creatine transport.

The two other patients had the two most common mutations (c.1222_1224 del TTC, p.F408del and c.1006_1008delAAC, p.N336del) identified in a global retrospective study of 101 males with X-linked creatine transporter deficiency [@bb0050]. This is the first report of these mutations in Israeli patients. Routine measurement of creatine by MRS should be considered in the evaluation of children with global developmental delay.

![Magnetic Resonance Spectroscopy (MRS) of the brain in patients with creatine transporter deficiency. A. Patient 1; B. Patient 2; C. Mother pf patient 2; D. Patient 3; E. Normal control. The arrow indicates the creatine peak. Note diminished creatine peak in all patients with creatine transporter deficiency and mildly reduced creatine peak in the mother of patient 2.](gr1){#f0005}

![Creatine uptake in fibroblasts from normal control and from patients with creatine transporter deficiency. Creatine (2 μM) transport was measured for 1 h. Non-specific uptake, measured in the presence of excess (2 mM) creatine, was subtracted from total uptake to calculate net uptake. Points are averages of triplicates ± SD. \*p \< 0.01 versus control using analysis of variance.](gr2){#f0010}

![Creatine transport in Hela cells. Creatine (2 μM) transport was measured for 30 min. Non-specific uptake, measured in the presence of excess (2 mM) creatine, was subtracted from total uptake to calculate net uptake. Points are averages of triplicates ± SD. \*p \< 0.01 versus Hela using analysis of variance.](gr3){#f0015}
